Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.
about
Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trialOxidative stress in schizophreniaDNA Damage and Repair in Schizophrenia and Autism: Implications for Cancer Comorbidity and BeyondIn Sickness and in Health: Perineuronal Nets and Synaptic Plasticity in Psychiatric DisordersBone Mineral Density in Schizophrenia: An Update of Current Meta-Analysis and Literature Review Under Guideline of PRISMAA Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical CorrelatesGenetic Polymorphisms of Glutathione-Related Enzymes (GSTM1, GSTT1, and GSTP1) and Schizophrenia Risk: A Meta-AnalysisThinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signalingMetabolic alterations associated with schizophrenia: a critical evaluation of proton magnetic resonance spectroscopy studiesInflammation and schizophreniaAttachment, Neurobiology, and Mentalizing along the Psychosis ContinuumIn vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophreniaErythropoietin: a candidate compound for neuroprotection in schizophreniaGlutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patientsMetabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophreniaNegative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS studySchizophrenia: redox regulation and volume neurotransmissionModifications of blood platelet proteins of patients with schizophrenia.Targeting Oxidative Stress and Aberrant Critical Period Plasticity in the Developmental Trajectory to Schizophrenia.Molecular substrates of schizophrenia: homeostatic signaling to connectivityAntipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotectionJuvenile antioxidant treatment prevents adult deficits in a developmental model of schizophreniaHow Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia.Reduction in phencyclidine induced sensorimotor gating deficits in the rat following increased system xc⁻ activity in the medial prefrontal cortex.Yi-gan san restores behavioral alterations and a decrease of brain glutathione level in a mouse model of schizophreniaGlutamate carboxypeptidase II and folate deficiencies result in reciprocal protection against cognitive and social deficits in mice: implications for neurodevelopmental disordersInhibitory interneurons, oxidative stress, and schizophrenia.Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia.Research in people with psychosis risk syndrome: a review of the current evidence and future directionsThe glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice.N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic miceGlutamatergic modulation of auditory information processing in the human brain.Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update.Oxidative stress and schizophrenia: recent breakthroughs from an old storyConsensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics.Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.Measurement of glutathione in human brain at 3T using an improved double quantum filter in vivo.Generation of superoxide anion radicals and platelet glutathione peroxidase activity in patients with schizophrenia.Meta-analysis of oxidative stress in schizophrenia.
P2860
Q21560890-DA6F3173-2824-4D24-BA3D-E1491BF7BC7FQ24595660-077AC529-8F0D-40D6-8575-FF5DD14C0BFDQ26743371-4C622E4A-9C11-4194-A8E3-7C4A540B39CFQ26769948-E4B29D64-11E8-490C-B283-324DDB1D7178Q26775158-79E3741A-2761-44EF-9FE5-4A1DDFFE4654Q26786354-DE1BCCB8-EE97-4013-B6B0-C801CFA5E941Q26795761-3CFEB5DA-E5A8-4724-9E2E-3077B39741BFQ26864995-7D8BF9F8-3402-4F55-91A8-3A0A5D3D0356Q26865740-94101FB7-2FD3-4C68-8A58-B00F1991D16EQ27002489-20AA5BDA-5AA7-43E8-9B75-81FFD5575148Q28069770-AF9EE20E-073C-4D49-804F-FC9C3519A3D1Q28083121-E4D7554D-F3A9-44F4-821C-8592ED681AE0Q28212816-E80C9204-59A7-4876-AAAA-A930DF95D554Q28257370-C75A55CF-1EB4-41B4-8484-4484C639C328Q28469040-C82A0B58-4E6F-4502-94A5-6936696AA388Q28472479-F0F52F54-BB19-494E-9184-3C3D9D680DD5Q28742799-F98E445F-9CD3-4D3E-8855-EAE39B8D7B8FQ30375094-695331C5-65F3-4D26-87CD-EE64AFC60224Q30380519-80F05934-9556-48DC-93A6-27157E9AE9EFQ30383611-D37702C1-6D09-4AFA-9516-7C4C71AC5E2CQ30386608-A411AB7E-0508-4BE7-B534-6A8353FB4B8FQ30403518-2E958ED8-E2B9-45D7-85D9-33A8E0310C1FQ30439924-EF0432D3-241E-4938-8966-FECED65EDAC5Q30440988-41FFDB4B-294E-401D-8E1E-40EBFB2EA551Q30452926-F052571E-C2B9-4EC0-9211-7258611AF9A9Q30453993-11460A58-2AFE-4C64-B76A-AE239464F13AQ30455112-95C2458E-FCD0-4793-8927-7051A81E5B45Q30457809-AAA93AB0-10DE-4E00-B4E1-A6D0A7FB9256Q30475598-78DED7B5-422E-4620-9EA1-1717BAABFFF0Q30481854-9F062C33-41DB-475B-A1F9-42C7C88365F3Q30504497-67ABF10C-CAAC-41D1-9C47-DD576D65AC25Q30506046-28088FC9-2412-43FA-A97F-BF632916AFECQ30685335-BD832836-40D9-4B51-B20E-D93FB82A207DQ30686416-12A955FB-2198-499D-8F0B-0905BD92BB57Q30774039-9C35AF9C-9A67-4444-A0D9-0F67AA83BCE9Q31108616-F17DF567-880D-489F-B2E0-695DA960C8CDQ33350202-0686FDC2-3C64-40B3-BBEC-01C4BDA38F29Q33414935-EAFFA161-B39D-4C4F-BD36-3DBFF4E62FC6Q33589462-3BD61E87-FF1F-4D1D-B581-C0A1913ED852Q33601360-EBFCF80C-8322-4020-9C21-6AD90078B109
P2860
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.
@en
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.
@nl
type
label
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.
@en
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.
@nl
prefLabel
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.
@en
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.
@nl
P2093
P2860
P1476
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo
@en
P2093
F Holsboer
M Kirsten-Krüger
P Boesiger
P2860
P304
P356
10.1046/J.1460-9568.2000.00229.X
P407
P577
2000-10-01T00:00:00Z